Delving into the Latest Updates on S1-Fc fusion protein (AbMax Biotechnology) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms-

Target

SARS-CoV-2 S protein

Action

inhibitors

Mechanism

SARS-CoV-2 S protein inhibitors(SARS-CoV-2 S protein inhibitors)

Therapeutic Areas

Infectious Diseases

Active Indication

Coronavirus Infections

Inactive Indication-

Originator Organization

Jingtiancheng Biotechnology (Beijing) Co., Ltd.

Active Organization

Jingtiancheng Biotechnology (Beijing) Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Author: Chen, Jianxin ; Li, Maohua ; Sun, Sean ; Gong, Sitao ; Hu, Yalin ; Ren, Wenlin ; Gao, Guang ; Zhao, Rongqing ; Fang, Feng ; Xia, Chenxi ; Chen, Yuxin ; Su, Junchi ; Gao, Wen ; Zhao, Gan ; Cheng, Xin ; Wang, Qi ; Chen, Jinggong ; He, Ailiang ; Sun, Hunter ; Jin, Xia ; Li, Min ; Sun, Yufei ; Sun, Le ; Gao, George F

The COVID-19 outbreak has become a global pandemic responsible for over 2,000,000 confirmed cases and over 126,000 deaths worldwide. In this study, we examined the immunogenicity of CHO-expressed recombinant SARS-CoV-2 S1-Fc fusion protein in mice, rabbits, and monkeys as a potential candidate for a COVID-19 vaccine. We demonstrate that the S1-Fc fusion protein is extremely immunogenic, as evidenced by strong antibody titers observed by day 7. Strong virus neutralizing activity was observed on day 14 in rabbits immunized with the S1-Fc fusion protein using a pseudovirus neutralization assay. Most importantly, in <20 days and three injections of the S1-Fc fusion protein, two monkeys developed higher virus neutralizing titers than a recovered COVID-19 patient in a live SARS-CoV-2 infection assay. Our data strongly suggests that the CHO-expressed SARS-CoV-2 S1-Fc recombinant protein could be a strong candidate for vaccine development against COVID-19.

100 Deals associated with S1-Fc fusion protein (AbMax Biotechnology)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Coronavirus Infections	Preclinical	China	Jingtiancheng Biotechnology (Beijing) Co., Ltd.	22 May 2023
Coronavirus Infections	Preclinical	United States	Jingtiancheng Biotechnology (Beijing) Co., Ltd.	22 May 2023